ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoantibodies and rheumatoid arthritis"

  • Abstract Number: 38 • 2018 ACR/ARHP Annual Meeting

    Pre-Clinical Clonally-Expanded aggrecan89-103–Specific CD4+ T Cells Are a Target for Autoimmune Arthritis Prevention

    Pascale Wehr1, Hendrik Nel1, Soi Cheng Law1, Diahann Jansen1, Nicole La Gruta2, Hugh Reid2, Jamie Rossjohn2 and Ranjeny Thomas1, 1University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, 2Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

    Background/Purpose: In the pre-clinical rheumatoid arthritis (RA) prodrome, autoantibodies and transient symptoms may develop. Pre-clinical autoantibody development suggests concomitant expansion of autoantigen-specific CD4+ follicular helper…
  • Abstract Number: 2791 • 2018 ACR/ARHP Annual Meeting

    Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression

    Alejandro Gomez, Sarah Kongpachith, Nithya Lingampalli, Cecilia Cisar and William H. Robinson, Department of Medicine, Stanford University, Stanford, CA

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are present in two-thirds of patients with rheumatoid arthritis (RA), and target proteins that have been post-translationally modified by the…
  • Abstract Number: 480 • 2017 ACR/ARHP Annual Meeting

    ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance

    Raul Castellanos-Moreira Sr.1, Virginia Ruiz-Esquide1, María José Gomara2, Sonia Cabrera-Villalba1, Sebastian C Rodriguez-Garcia1, Georgina Salvador3, Andrea Cuervo1, Julio Ramírez1, M. Victoria Hernández1, Juan Cañete1, Isabel Haro2 and Raimon Sanmartí1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, 3Hospital Universitario Mutua Terrassa, Barcelona, Spain

    Background/Purpose: Autoantibodies (RF or ACPA) are found in sera from patients with palindromic rheumatism (PR) but there are no studies analyzing the presence of Anti-carbamylated…
  • Abstract Number: 2847 • 2014 ACR/ARHP Annual Meeting

    Survivin Co-Ordinates Formation of Follicular T-Cells in Rheumatoid Arthritis

    Maria Bokarewa1, Karin Andersson2, Malin Erlandsson2, Mattias Svensson2, Nicola Cavallini3 and Mikael Brisslert2, 1Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden, 2Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 3Rheumatology and Inflammation Research, University of Göteborg, Göteborg, Sweden

    Background/Purpose Survivin is a proto-oncogene that regulates cell division and apoptosis. Recently, survivin has emerged as a biomarker of persistently active and joint destructive rheumatoid…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology